This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
by Zacks Equity Research
Roche advances vamikibart toward potential US approval after phase III trials show sustained vision improvements, reduced retreatment needs and a favorable safety profile.
RHHBYPositive Net Change BAYRYPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Skyrizi & Rinvoq Drive AbbVie's Top-Line Growth in Q3?
by Sundeep Ganoria
ABBV's Skyrizi and Rinvoq are expected to drive Q3 growth, offset Humira's ongoing decline and face rising competition in the immunology market.
ABBVPositive Net Change JNJPositive Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
by Sundeep Ganoria
MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.
MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change RHHBYPositive Net Change MRKPositive Net Change
biotechs medical pharmaceuticals vaccines
Cancer Stocks to Consider as Oncology Innovation Accelerates
by Kinjel Shah
Oncology stocks are gaining relevance as cancer care evolves, with Pfizer, Merit Medical Systems and Abbott advancing treatments, diagnostics and screening technologies.
ABTPositive Net Change PFEPositive Net Change MMSINegative Net Change AZNPositive Net Change NVSPositive Net Change JNJPositive Net Change ABBVPositive Net Change
biotechs cancer pharmaceuticals
Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio
by Zacks Equity Research
VTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
VTRSPositive Net Change ALNYPositive Net Change PCRXPositive Net Change AMRNNegative Net Change
biotechnology biotechs medical pharmaceuticals
4 CNS Drug Stocks Worth Watching This World Mental Health Day
by Ahan Chakraborty
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
ALKSNegative Net Change NBIXPositive Net Change ACADPositive Net Change AXSMPositive Net Change
biotechnology biotechs medical pharmaceuticals
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
by Zacks Equity Research
Roche wins FDA approval for Tecentriq in stage III dMMR colon cancer, with trial data showing a 50% lower risk of recurrence or death.
RHHBYPositive Net Change PFEPositive Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
ARGX Stock Down on Stopping Late-Stage Autoimmune Disease Study
by Zacks Equity Research
argenx shares tumble 12% after discontinuing its late-stage Sjogren's disease study, while positive FB102 data in celiac disease offer a contrasting pipeline development.
ARGXPositive Net Change ALNYPositive Net Change CRSPPositive Net Change
biotechnology biotechs medical pharmaceuticals
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe
by Zacks Equity Research
Halozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.
HALOPositive Net Change JNJPositive Net Change MRKPositive Net Change ARGXPositive Net Change
biotechs medical pharmaceuticals
Bayer Seeks Kerendia Label Expansion in Non-Diabetic CKD
by Zacks Equity Research
BAYRY's Kerendia label expansion moves forward as FDA accepts an application for CKD patients without diabetes.
BAYRYPositive Net Change REGNPositive Net Change JNJPositive Net Change
biotechs medical pharmaceuticals